Amlodipine Decreases Iron Uptake and Oxygen Free Radical Production in the Heart of Chronically Iron Overloaded Mice

Biological Research For Nursing

Volumn 3, Issue 4, 2002, Pages 189-197

  Crowe, Sarah ^a   Bartfay, Wally J ^b  

^a KINGSTON GENERAL HOSPITAL   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

aldehydes; amlodipine; cardiomyopathy; free radicals; iron overload

Indexed keywords

ALDEHYDE; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; FREE RADICAL; IRON; REACTIVE OXYGEN METABOLITE;

ANIMAL; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CHEMISTRY; DRUG EFFECT; EVALUATION; HEART MUSCLE; HEMOCHROMATOSIS; METABOLISM; MOUSE; OXIDATION REDUCTION REACTION;

ALDEHYDES; AMLODIPINE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CARDIOMYOPATHIES; FREE RADICALS; HEMOCHROMATOSIS; IRON; MICE; MODELS, ANIMAL; MYOCARDIUM; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES;

EID: 0036527536     PISSN: 10998004     EISSN: None     Source Type: Journal    
DOI: 10.1177/109980040200300404     Document Type: Article

References (71)

1. Adams PC, Valberg LS. 1996. Evolving expression of hereditary hemochromatosis. Sem Liver Dis 16: 47-54.
2. Andrews NA. 1999. Disorders of iron metabolism. N Engl J Med 341: 1986-1995.
3. Araujo GC, Nogueira AR, Nobrega JA. 2000. Single vessel procedure for acid-vapour partial digestion in a focused microwave: Fe and Co determination in biological samples by ETAAS. Analyst 125: 1861-1864.
4. Ball A, Sole MJ. 1998. Oxidative stress and the pathogenesis of heart failure. Cardiol Clin 16: 655-675.
5. Bartfay WJ, Bartfay E. 2000a. Iron-overload cardiomyopathy: evidence for a free radical mediated mechanism of injury and dysfunction in a murine model. Biol Res Nurs 2(1):1-11.
6. Bartfay WJ, Bartfay E. 2000b. Systemic oxygen free radical production in iron-loaded mice. West J Nurs Res 22: 927-937.
7. Bartfay WJ, Bartfay E. 2002. Decreasing effects of iron toxicosis on selenium and glutathione peroxidase activity. West J Nurs Res 24: 119-131.
8. Bartfay WJ, Butany J, Sole MJ, Hou D, Bartfay E, Liu PP. 1999. A biochemical, histochemical and electron microscopic study on the effects of iron-loading in heart of mice. Cardiovasc Pathol 8: 305-314.
9. Bartfay WJ, Dawood FD, Wen WH, Lehotay DC, Hou D, Bartfay E, Luo XP, Backx PH, Liu PP. 1999. Cardiac function and cytotoxic aldehyde production in a murine model of chronic iron-overload. Cardiovasc Res 43: 892-900.
10. Bartfay WJ, Hou D, Brittenham GM, Bartfay E, Sole MJ, Lehotay D, Liu PP. 1998. The synergistic effects of vitamin E and selenium in iron-loaded mouse hearts. Can J Cardiol 14: 937-941.
11. Bartfay WJ, Hou D, Lehotay DC, Bartfay E, Luo XP, Liu PP. 2000. Cardioprotective effects of selenium and morin hydrate in a murine model of chronic iron overload. JT race Elem Exp Med 13: 285-297.
12. Bartfay WJ, Lehotay D, Hou D, Backx P, Liu PP, 2000. Cytotoxic aldehyde generation in heart following acute iron-loading. J Trace Elem Biol Med 14(1):14-20.
13. Bartfay WJ, Lehotay DC, Sher GD, Bartfay E, Tyler B, Luo XP, Liu PP. 1999. Comparison of cytotoxic aldehyde generation in beta-thalassemia patients chelated with deferoxamine or deferiprone (L1) versus no chelation. Hematology 4: 67-76.
14. Blasig IE, Grune T, Schonheit K, Rohde E, Jakstadt M, Haseloff RF, Siems WB. 1995. 4-hydroxynonenal, a novel indicator of lipid peroxidation for reperfusion injury of the myocardium. Am J Ph ysiol 269: H14-H22.
15. Bothwell TH, MacPhail AP. 1998. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Sem Hematol 35(1):55-71.
16. Bottomley SS. 1998. Secondary iron overload disorders. Sem Hematol 35: 77-86.
17. Burkitt MJ, Mason RP. 1991. Direct evidence for in vivo hydroxyl generation in experimental iron overload: an ESR spin-trapping investigation. Proc Natl Acad Sci U S A 88: 8440-8444.
18. Byler RM, Sherman NA, Wallner JS, Horwitz LD. 1994. Hydrogen peroxide cytotoxicity is iron dependent. Am J Ph ysiol 35: H121-H127.
19. Crowe S, Bartfay WJ. 2001a. The use of L-type calcium channel blockers in preventing entry of nontransferrin bound iron into the myocardium [abstract]. Kingston General Hospital Nursing Services and Queen's University School of Nursing 3rd Nursing Research Conference, Building Clinical Practice Knowledge through Research; 22 May 2001; Kingston, Ontario, Canada.
20. Crowe S, Bartfay WJ. 2001b. The use of L-type calcium channel blockers in preventing entry of nontransferrin bound iron into the myocardium [oral presentation]. Fourth Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen's University; 30 May 2001; Kingston, Ontario, Canada.
21. De Luca C, Filosa A, Grandinetti M, Maggio F, Lamba M, Passi S. 1999. Blood antioxidant status and urinary levels of catecholamine metabolites in beta-thalassemia. Free Radical Res 30: 453-462.
22. Demougeot C, Marie C, Beley A. 2000. Importance of iron location in iron-induced hydroxyl radical production by brain slices. Life Sci 67: 399-410.
23. De Valk B, Addicks MA, Gosriwatana I, Lu S, Hider RC, Marx JJ. 2000. Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes. Eur J Clin Invest 30: 248-251.
24. Digiesi V, Fiorillo C, Cosmi L, Rossetti M, Lenuzza M, Guidi D, Pace S, Rizzuti G, Nassi P. 2000. Reactive oxygen species and antioxidant status in essential arterial hypertension during therapy with dihydropyridine calcium channel antagonists. Clin Ther 151(1):15-18.
25. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kusher JP. 1988. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 318: 355-362.
26. Esterbauer H. 1993. Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr 57: 779S-786S.
27. Farghali H, Kmonickova E, Lotkova H, Marinek J. 2000. Evaluation of calcium channel blockers as potential hepatoprotective agents in oxidative stress injury of perfused hepatocytes. Physiol Res 49: 261-268.
28. Feder JN, Gnirke A, Thomas W. 1996. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genetics 13: 399-408.
29. Gordeuk VR. 1992. Hereditary and nutritional iron overload. Baillieres Clin Haematol 5: 169-186.
30. Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, Hider RC. 1999. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem 273: 212-220.
31. Goyer RA. 1995. Nutrition and metal toxicity. Am J Clin Nutr 61: 646S-650S.
32. Gutteridge JMC. 1993. Free radicals in disease processes: a complication of cause and consequence. Free Radical Res 19: 141-158.
33. Gutteridge JMC, Rowley DA, Griffiths E, Halliwell B. 1985. Low-molecular-weight complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci 68: 463-467.
34. Halliwell B. 1994. Free radicals, antioxidants, and human disease: curiosity, cause or consequence? Lancet 344: 721-724.
35. Halliwell B. 1997. Antioxidants and human disease: a general introduction. Nutr Rev 55: S44-S52.
36. Halliwell B, Chirico S. 1993. Lipid peroxidation: it's mechanism, measurement, and significance. Am J Clin Nutr 57: 715S-725S.
37. Herbert V, Shaw S, Jayatilleke E, Stopler-Kasdan T. 1994. Most free radical injury is iron mediated: it is promoted by iron, hemin, holoferritin and vitamin C, and inhibited by desferoxamine and apoferritin. Stem Cells 12: 289-303.
38. Hershko C, Link G, Cabantchik I. 1998. Pathophysiology of iron overload. Ann N Y Acad Sci 850: 191-201.
39. Hollan SR. 1997. Transfusion-associated iron overload. Curr Opinion Hematol 4: 436-441.
40. Horwitz DL, Rosenthal EA. 1999. Iron-mediated cardiovascular injury. Vasc Med 4: 93-99.
41. Kaplan J, Jordan I, Sturrock A. 1991. Regulation of the transferrin-independent iron transport system in cultured cells. J Biol Chem 266: 2997-3004.
42. Kehrer JP. 2000. The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 149(1):43-50.
43. Kim E, Giri SN, Pessah IN. 1995. Iron (II) is a modulator of ryanodine-sensitive channels of cardiac muscle sarcoplasmic reticulum. Toxicol Appl Pharmacol 130: 57-66.
44. Lawrence D, Rosenthal EA. 1999. Iron-mediated cardiovascular injury. Vasc Med 4: 93-99.
45. Lesnefsky EJ. 1994. Tissue iron overload and mechanisms of iron-catalyzed oxidative injury. Adv Exp Med Biol 366: 129-146.
46. Link G, Athias P, Grynberg A, Hershko C, Pinson A. 1996. Iron-loading modifies beta-adrenergic responsiveness in cultured ventricular myocytes. Cardiosci 2: 185-188.
47. Link G, Pinson A, Hershko C. 1985. Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med 106: 147-153.
48. Linpisarn S, Satoh K, Mikami T, Orimo H, Shinjo S, Yoshino Y. 1991. Effects of iron on lipid peroxidation. Int J Hematol 54: 181-188.
49. Liu P, Olivieri N. 1994. Iron overload cardiomyopathies: new insights into an old disease. Cardiovasc Drugs Ther 8: 101-110.
50. Livrea MA, Tesoriere L, Pintaudi AM, Calabrese A, Maggio A, Freisleben HJ, D-Arpa D, D'Anna R, Bongiorno A. 1996. Oxidative stress and antioxidant status in beta-thalassemia major: iron-overload and depletion of lipid-soluble antioxidants. Blood 88: 3608-3614.
51. Luo XP, Yazdanpanah M, Bhooi N, Lehotay DC. 1995. Determination of aldehydes and other lipid peroxidation products in biological samples by gas chromatography-mass spectrometry. Anal Biochem 228: 294-298.
52. Madani TAA, Bormanis J. 1997. Reversible severe hereditary hemochromatotic cardiomyopathy. Can J Cardiol 13: 391-394.
53. Mason RP, Walter MF, Trumbore MW, Olmstead EG, Mason PE. 1999. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 31: 275-281.
54. McCord JM. 1996. Effects of positive iron status at a cellular level. Nutr Rev 54: 85-88.
55. Meneghini R. 1997. Iron homeostasis, oxidative stress, and DNA damage. Free Radical Biol Med 23: 783-792.
56. Montgomery DC. 1991. Design and analysis of experiments. 3rd ed. Toronto: John Wiley & Sons.
57. Olfert ED, Cross BM, McWilliams AA. 1999. Canadian Council on Animal Care: guide to the care and use of experimental animals. 2nd ed. Ottawa: Bradda Printing Services.
58. Parkes JG, Olivieri NF, Templeton DM. 1997. Characterization of Fe 2+and Fe 3+ transport by iron-loaded cardiac myocytes. Toxicology 117(2-3):141-151.
59. Quinlan GJ, Mumby S, Pepper J, Gutteridge JM. 1994. Plasma 4-hydroxy-2-nonenal levels during cardiopulmonary bypass, and their relationship to the iron-loading of transferrin. Biochem Mol Biol Int 34: 1277-1282.
60. Randell EW, Parkes JG, Olivieri NF, Templeton DM. 1994. Uptake of nontransferrin-bound-iron by both reductive and nonreductive processes is mediated by intracellular iron. J Biol Chem 269: 16046-16053.
61. Requena JR, Fu MX, Ahmed MU, Jenkins AJ, Lyons TL, Thorpe SR. 1996. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol Dial Transplant 11: 48-53.
62. Savigni DL, Morgan EH. 1996. Mediation of iron uptake and release in erythroid cells by photodegradation products of nifedipine. Biochem Pharmacol 51: 1701-1709.
63. Sevanian A, Shen L, Ursini F. 2000. Inhibition of LDL oxidation and oxidized LDL-induced cytotoxicity by dihydropyridine calcium antagonists. Pharm Res 17: 999-1006.
64. Smith J, Konstam M. 2000. Calcium channel blockers in heart failure: has the bridge been crossed? In: McMurray JVJ, Cleland JGF, editors. Heart failure in clinical practice. 2nd ed. London: Marin Dunitz. p 281-298.
65. Sugawara H, Tobise K, Kikuchi K. 1996. Antioxidant effects of calcium antagonists on rat myocardial membrane lipid peroxidation. Hypertens Res 19: 223-228.
66. Tong MI, Zhang J, Weglicki WB. 2002. Protective effects of dihydropyridine Ca-blockers against endothelial cell oxidative injury due to combined nitric oxide and superoxide. Pharmacol Res 45(1):27-33.
67. Tsushima RG, Wilkenden AD, Bouchard RA, Oudit GY, Liu PP, Backx P. 1999. Modulation of iron uptake in heart by L-type Ca 2+ channel modifiers: possible implications of iron-overload. Circ Res 11: 1302-1309.
68. Winegar BD, Kelly R, Larsen JB. 1991. Block of current through single calcium channels by Fe, Co and Ni. J Gen Physiol 97: 351-367.
69. Wolff SP, Dean RT. 1986. Fragmentation of proteins by free radicals and its effect on their susceptibility to enzymic hydrolysis. Biochem J 234: 399-403.
70. Yazdanpanah M, Luo XP, Lau R, Greenberg M, Fisher LJ, Lehotay DC. 1997. Cytotoxic aldehydes as possible markers for childhood cancer. Free Radical Biol Med 23: 870-878.
71. Young IS, Trouton TG, Torney JJ, McMaster D, Callender M, Trimble ER. 1994. Antioxidant status and lipid peroxidation in hereditary hemochromatosis. Free Radical Biol Med 16: 393-397.